Abstract: Provided herein are nanoparticle compositions comprising a pharmaceutically acceptable carrier and a compound of Formula (II).

Abstract: Disclosed herein, in certain embodiments, are anti-CD47 antibodies, nucleic acid polymers encoding the antibodies, and vectors for expressing the same. In some embodiments, also disclosed herein include pharmaceutical compositions comprising the anti-CD47 antibodies and methods of treatment.

Abstract: Provided herein are nanoparticle compositions comprising an organophosphate compound and pharmaceutically acceptable carriers.

Abstract: Provided herein are nanoparticle compositions comprising a pharmaceutically acceptable carrier and a compound of Formula (I): A-L-B.

Abstract: Provided herein are nanoparticle compositions comprising an organophosphate compound and pharmaceutically acceptable carriers.

Abstract: Provided herein are nanoparticle compositions comprising organophosphate compounds, and pharmaceutically acceptable carriers.

Abstract: Provided herein are nanoparticle compositions comprising modulators of the Bcl-2 family proteins, and pharmaceutically acceptable carriers.

Abstract: This disclosure provides nanoparticle compositions comprising nucleoside or nucleotide prodrugs, their use as medicinal agents, and processes for their preparation. The disclosure also provides for the use of the nanoparticle compositions described herein as medicaments and/or in the manufacture of medicaments for the treatment of a variety of diseases, including cancer and viral infections. Provided in one aspect is a composition comprising nanoparticles, wherein the nanoparticles comprise a prodrug of a nucleoside or nucleotide, and a pharmaceutically acceptable carrier; wherein the pharmaceutically acceptable carrier comprises albumin.

Abstract: Disclosed herein are polynucleic acid molecules, plasmids, vectors, compositions, methods, and kits for expressing a target protein. In some instances, also described herein are polynucleic acid molecules, plasmids, vectors, compositions, methods, and kits for enhancing the expression of a target protein.

Abstract: Methods and assays for detecting ?-secretase (BACE-1) activity in body fluids or tissue extracts from individuals, particularly individuals who have Alzheimer's disease, are disclosed. A truncated form of BACE-1 was isolated that can be used as a biomarker for Alzheimer's disease.